Advanced High-Grade Serous Ovarian Cancer in a Frail Patient: Primary Debulking or Neoadjuvant Chemotherapy
A 68-year-old woman presents with six weeks of abdominal bloating and early satiety. CT shows a 12 cm complex left adnexal mass, omental caking, moderate ascites, and a 2 cm nodule on the right hemidiaphragm; there is no bowel obstruction and no hydronephrosis. CA-125 is 1,180 U/mL and CEA is 1.8 ng/mL. Omental core biopsy shows high-grade serous carcinoma. She has chronic obstructive pulmonary disease requiring 2 L/min of home oxygen, a BMI of 34, and an albumin of 2.7 g/dL; her ECOG performance status is 2 and she lives independently but tires after one block of walking. She wants everything possible done and is reluctant to hear about delaying surgery. The gynecologic oncology team believes complete cytoreduction would require diaphragm stripping and possibly a bowel resection, lasting about five hours, and anesthesia considers her high risk for that operation.
1. How do you decide between primary cytoreductive surgery and neoadjuvant chemotherapy in this patient? What specific findings and evidence drive the recommendation, and what does the biopsy contribute?
Read the worked answer
The decision rule. The goal of primary debulking is complete cytoreduction with no visible residual disease, because residual disease is the strongest prognostic factor. Primary surgery is favored when complete resection is realistically achievable, performance status is 0-1, nutrition is adequate, there is no major comorbidity, and the patient can tolerate a long operation and recovery. Neoadjuvant chemotherapy is favored when those conditions are not met or when preoperative assessment suggests a high likelihood of suboptimal cytoreduction.
Her case. ECOG 2, albumin 2.7 g/dL, home oxygen, obesity, a large-volume upper abdominal tumor burden, and anesthesia's assessment all point away from a five-hour primary debulking. Randomized evidence (EORTC 55971, CHORUS) shows that neoadjuvant chemotherapy with interval debulking is not inferior to primary surgery in advanced disease and reduces perioperative morbidity; the SCORPION trial found better progression-free survival and fewer complications with neoadjuvant treatment in patients with high tumor load. The counterargument, that overall survival may be somewhat better when complete primary cytoreduction is achieved at high-volume centers, does not apply to a patient who is unlikely to reach the recovery room in a condition to receive chemotherapy.
Role of the biopsy. Image-guided core biopsy establishes the diagnosis without surgery, excludes a gastrointestinal primary (a normal CEA and PAX8-positive staining help), and, critically, allows germline and somatic BRCA and homologous recombination deficiency testing before treatment, which shapes maintenance therapy. A diagnostic laparoscopy by an experienced surgeon is an alternative way to score resectability but is not necessary here. Frame neoadjuvant treatment as the first phase of treatment rather than as delay, and involve her in the decision.
2. She begins carboplatin and paclitaxel. After three cycles CA-125 falls to 90 U/mL and CT shows decreased omental caking and ascites. What is the plan for interval cytoreduction, and what is the role of bevacizumab and PARP inhibitors based on her BRCA status?
Read the worked answer
Interval debulking. Response after three to four cycles is the expected outcome and supports proceeding to interval cytoreductive surgery with the same intent of complete resection. Timing is typically after three or four cycles, with the aim of completing six cycles postoperatively. If she had stable disease rather than response, surgery would still generally be offered; if she had progressed, surgery would be abandoned.
Bevacizumab. Adding bevacizumab to chemotherapy and continuing it as maintenance improves progression-free survival, with the largest benefit in high-risk disease such as stage IV or suboptimal cytoreduction (GOG-218, ICON7). It increases hypertension, proteinuria, thrombosis, and bowel perforation risk, so it is usually started with cycle two or later and avoided in patients with extensive bowel involvement or recent surgery; her COPD and performance status warrant caution.
PARP inhibitors. Germline and somatic BRCA testing and homologous recombination deficiency testing should already be back. If she is BRCA-mutated, maintenance olaparib or niraparib substantially prolongs progression-free survival (SOLO1 for newly diagnosed BRCA-mutated disease, PRIMA for niraparib across the newly diagnosed population). If she is HRD-positive without a BRCA mutation, olaparib plus bevacizumab is supported by PAOLA-1. If HRD-negative, the benefit is smaller but niraparib still shows a progression-free survival advantage in PRIMA and can be discussed with attention to anemia, thrombocytopenia, and fatigue.
Supportive care. Address nutrition, pulmonary optimization, and VTE prophylaxis around surgery, and screen for a hereditary syndrome with genetic counseling regardless of her age.
3. What if imaging after three cycles instead shows new liver lesions and a rising CA-125? How does that change management?
Read the worked answer
Interpretation. New liver lesions with a rising CA-125 during first-line platinum-taxane therapy indicate platinum-resistant progression, which is a different disease trajectory from a responding patient. In this setting interval debulking is not indicated: surgery does not improve survival when disease is progressing on chemotherapy and may delay effective systemic treatment and worsen quality of life.
Management. Stop the current regimen and switch to a non-cross-resistant agent. Reasonable options in platinum-resistant high-grade serous cancer include weekly paclitaxel, pegylated liposomal doxorubicin, topotecan, gemcitabine, or trabectedin, alone or with bevacizumab if she has not already received it and has no contraindication. Re-biopsy or cell-free DNA testing for BRCA reversion mutations is reasonable, particularly if she was BRCA-mutated and responding previously. Clinical trial enrollment should be raised early.
Goals of care. Given her comorbidity, performance status, and now chemotherapy-refractory disease, this is the moment for an explicit goals-of-care conversation rather than another escalation. Discuss expected prognosis, the difference between disease control and cure, symptom management for ascites and bowel function, and early palliative care involvement, which improves quality of life and can prolong survival in advanced cancer. Revisit her earlier wish for everything possible in concrete terms, and document her preferences and a health care proxy.